Pay in 4 interest-free payments of $7.08 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Agonists Exendin-4 (subsequently renamed exenatide, the first FDA approved incretin mimetic), Liraglutide (a longacting DPP-4-resistant GLP-1 receptor agonist), CJC-1131 (a GLP-1 analog engineered for covalent coupling to albumin), Albiglutide (originally referred to as albugon, a recombinant human albumin-GLP-1 protein), ZP10 (an exendin-4 derivative), BIM51077 (subsequently renamed taspoglutide), LY315902 (a DPP-4-resistant GLP-1 analog), LY2428757 (a pegylated GLP-1), LY2199265 (Dulaglutide, an Fc immunoglobulin fusion protein), Semaglutide (a synthetic peptide similar to GLP-1), Lixisenatide (a synthetic peptide similar to exandin-4), and Tirzepatide (LY3298176, a dual agonist of GIP and GLP-1 receptors)
The Evolution of Ozempic and Its Off-Label Use Initially designed and approved in 2017 for Type 2 diabetes treatment, Ozempics unintended side effect of appetite suppression and consequential weight loss was promptly observed by clinicians
IGF-1 LR3 IGF-1R
Providers will screen you out if you have a personal or family history of medullary thyroid cancer, Multiple Endocrine Neoplasia syndrome type 2, or pancreatitis
US$ 28.85
US$ 25.15
US$ 22.48
US$ 26.53
US$ 21.25
US$ 22.68
US$ 29.30
US$ 24.17
